Lexicon Pharmaceuticals
biopharmaceutical company
LXRX Nasdaq
ISIN US5288723027 SEC CIK 1062822
Follow Lexicon Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$11.3M
−20.7% vs same quarter last year
Net income
−$14M
−9.7% vs same quarter last year
EPS, diluted
−$0.03
+25% vs same quarter last year
Operating cash flow
−$8.1M
+66.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $49.8M | −$50.3M |
| FY24 | $6M | −$200.4M |
| FY23 | $1.1M | −$177.1M |
| FY22 | $0 | −$101.9M |
| FY21 | $0 | −$87.8M |
| FY20 | $23.4M | −$58.6M |
| FY19 | $32.3M | $130.1M |
| FY18 | $26.6M | −$120.5M |
| FY17 | $15.9M | −$123M |
| FY16 | $0 | −$131.4M |
| FY15 | $130M | −$4.7M |
| FY14 | $22.9M | −$100.3M |
| FY13 | $2.2M | −$104.1M |
| FY12 | $1.1M | −$110.2M |
| FY11 | $1.8M | −$116.2M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 99.4% | −98.2% | −101.1% |
| FY24 | 89.7% | −3284.7% | −3339.5% |
| FY23 | 92.3% | −15473% | −15956.7% |
| FY22 | - | - | - |
| FY21 | - | - | - |
| FY20 | 91.8% | −204.2% | −250.3% |
| FY19 | 90% | 437.5% | 402.5% |
| FY18 | 90.6% | −388.5% | −453.5% |
| FY17 | 88% | −822.1% | −774% |
| FY16 | - | - | - |
| FY15 | 100% | 1.1% | −3.6% |
| FY14 | - | −439.2% | −438.8% |
| FY13 | - | −4607.2% | −4686.1% |
| FY12 | - | −9955.5% | −10120.4% |
| FY11 | - | −6170.6% | −6285.3% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$67.9M |
| FY24 | −$179.8M |
| FY23 | −$162.4M |
| FY22 | −$90.2M |
| FY21 | −$88.2M |
| FY20 | −$143.1M |
| FY19 | $113.7M |
| FY18 | −$148.7M |
| FY17 | −$185.6M |
| FY16 | −$175.9M |
| FY15 | $183.9M |
| FY14 | −$75.7M |
| FY13 | −$92.8M |
| FY12 | −$95M |
| FY11 | −$89.1M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | $1.7M |
| FY23 | $824K |
| FY22 | $864K |
| FY21 | $2.7M |
| FY20 | $1M |
| FY19 | $941K |
| FY18 | $972K |
| FY17 | $1.7M |
| FY16 | $621K |
| FY15 | $357K |
| FY14 | $887K |
| FY13 | $873K |
| FY12 | $285K |
| FY11 | $108K |
- Lexicon Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Lexicon Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −101.1% | −30.6% |
| FY24 | −3339.5% | −47% |
| FY23 | −15956.7% | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.8% |
| FY20 | −250.3% | −62.2% |
| FY19 | 402.5% | −46.2% |
| FY18 | −453.5% | −49.6% |
| FY17 | −774% | −45.9% |
| FY16 | - | −36% |
| FY15 | −3.6% | −37.8% |
| FY14 | −438.8% | −35.5% |
| FY13 | −4686.1% | −37.1% |
| FY12 | −10120.4% | −29.1% |
| FY11 | −6285.3% | −27.9% |